Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrapulmonary penetration of ceftolozane/tazobactam vs ceftazidime/avibactam in continuous infusion for nosocomial pneumonia
2021-006908-32Phase 4Active
- Sponsor
- Sonia Luque Pardos
- Start
- Feb 2022
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ceftolozane + tazobactam and ceftazidime + avibactam in hospital-acquired pneumonia (HAP) (2 arms), sponsored by Sonia Luque Pardos. Primary endpoint: Clinical response. Started Feb 2022; status: active.
02
Drugs
ceftolozane + tazobactamceftazidime + avibactam
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on 2021-006908-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006908-32.